Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C8H14N4O2 |
Molar mass | 198.222 g/mol |
3D model (JSmol) | |
| |
|
WikiDoc Resources for Mebicar |
Articles |
---|
Most recent articles on Mebicar |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Mebicar at Clinical Trials.gov Clinical Trials on Mebicar at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mebicar
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating Mebicar Risk calculators and risk factors for Mebicar
|
Healthcare Provider Resources |
Causes & Risk Factors for Mebicar |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Mebicar (mebicarum) is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in the Russian Federation under the brand name Adaptol.[1] It is not approved for use in the United States or European Union.
Mebicar has an effect on the structure of limbic-reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, increases the brain serotonin level, and does not elicit cholinolytic action.[2]
Mebicar purportedly has anti-anxiety (anxiolytic) properties.[2][3][4][5][6] It is also used to aid smoking cessation.[1] In addition Mebicar may be useful in the treatment of ADHD symptoms.[7] In contrast with typical anxiolytic medication like benzodiazepines Mebicar is non-habit forming, non-sedating and does not impair motor function.[3][1]